Exciting Developments from Ascletis on ASC47
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") has made notable strides in the field of obesity treatment with research presentations on ASC47, a promising drug candidate for weight loss. This innovative medication targets adipose tissue and preserves muscle, offering a dual approach to managing obesity. At the recent 32nd European Congress on Obesity (ECO 2025), held in Malaga, significant findings were revealed through oral and poster presentations.
Details of the Oral Presentation
Title and Highlights
The oral presentation titled ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice was met with much anticipation. The findings suggest that ASC47 is capable of delivering substantial weight loss while maintaining lean muscle mass, a crucial development for those struggling with obesity.
Key points from the presentation included:
- Abstract Number: 0254
- Session: T1 Abstract Session: Novel Drugs. The Seeds for the Future Are Here
- Presentation Time: 11:30-13:00 Malaga Time on May 13, 2025
- Presenter: Jinzi Jason Wu
Insights from the Poster Presentation
First-in-Human Study
In addition to the oral presentation, Ascletis showcased the findings from a guided poster presentation titled ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study. This research presents ASC47's potential in healthy individuals, marking a significant step toward broader clinical applications.
Details of this presentation included:
- Abstract Number: 0816
- Session: Track Specific Poster Networking Session
- Presentation Time: 18:00-19:10 Malaga Time on May 13, 2025
- Presenter: Jinzi Jason Wu
The Science Behind ASC47
ASC47 is a groundbreaking therapeutic agent, characterized as an adipose-targeted, ultra-long-acting thyroid hormone receptor beta (THR?) agonist. Developed in-house at Ascletis, it exhibits a unique mechanism that enables high concentrations of the drug within adipose tissue, promoting effective weight loss. Recent Phase Ib studies using ASC47 involved participants with elevated low-density lipoprotein cholesterol (LDL-C), demonstrating promising results.
One of the highlights of the ASC47 journey has been the clearance of its U.S. Investigational New Drug (IND) application for combination therapy with semaglutide for obesity treatment, marking a crucial milestone in its development timeline.
About the European Congress on Obesity
The European Congress on Obesity (ECO) is a premier event organized by the European Association for the Study of Obesity (EASO). Since its establishment in 1986, the ECO serves as a vital platform for sharing cutting-edge research, innovations, and effective strategies in obesity management and prevention, bringing together professionals from various disciplines.
Overview of Ascletis Pharma Inc.
Ascletis is a forward-thinking biotech company listed on the Hong Kong Stock Exchange (1672.HK). Its comprehensive approach encompasses the entire lifecycle of drug development, from discovery to manufacturing. With a strong focus on metabolic diseases, Ascletis is addressing pressing healthcare needs globally. The company is actively developing multiple clinical-stage drug candidates, paving the way for innovative solutions in this critical medical field.
Frequently Asked Questions
What is ASC47?
ASC47 is a weight loss drug candidate developed by Ascletis that is designed to target fat tissue while preserving muscle mass.
When was the presentation at the European Congress on Obesity held?
The presentation occurred on May 13, 2025, during the 32nd European Congress on Obesity.
Who was the presenter of the findings on ASC47?
The findings were presented by Jinzi Jason Wu, a key figure in the development of ASC47.
What are the unique properties of ASC47?
ASC47 is distinguished by its ability to achieve high concentrations in adipose tissue while being selective in its action as a THR? agonist.
How does ASC47 fit into obesity treatment?
ASC47 has the potential to transform obesity treatment by promoting effective weight loss without sacrificing lean muscle mass, addressing a key concern in obesity management.
